PFIZER · Healthcare
Pfizer Ltd. reported revenue of ₹538 cr for October to December 2024, −0.4% on the year and −8.7% on the quarter.
Operating profit (EBITDA) was ₹146 cr, a margin of 27.1%, −120 bps on the year and −495 bps on the quarter. Over the last 7 quarters the margin has ranged from 20.9% to 34.6%, averaging 29.5%. Operating costs grew +1.3%, faster than revenue at −0.4%, so operating profit grew less than sales.
Net profit was ₹128 cr, −1.5% on the year and −19.0% on the quarter, with earnings per share of ₹27.89. Profit before other income, one-offs and tax fell 2.3%, so the profit growth came from the business itself. The tax rate of 26% is in line with its recent average.
On earnings per share of ₹134.54 over the last four quarters, the stock at ₹3,785.00 trades at 28.1 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹575 cr | ₹540 cr | ₹547 cr | ₹563 cr | ₹589 cr | ₹538 cr | ₹592 cr | ₹603 cr | ₹642 cr | ₹645 cr | ₹629 cr | ₹653 cr |
| YoY | — | — | — | +6% | +2% | −0% | +8% | +7% | +9% | +20% | +6% | +8% |
| EBITDA margin | 31.8% | 28.3% | 34.6% | 31.4% | 32.1% | 27.1% | 38.5% | 34.8% | 35.8% | 35.3% | 37.5% | 38.0% |
| Other income, % of PBT | 18% | 25% | 31% | 21% | 20% | 25% | 51% | 26% | 16% | −10% | 19% | 16% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% | 26% |
| Net profit | ₹149 cr | ₹130 cr | ₹179 cr | ₹151 cr | ₹158 cr | ₹128 cr | ₹331 cr | ₹192 cr | ₹189 cr | ₹142 cr | ₹200 cr | ₹204 cr |
| YoY | — | — | — | +61% | +6% | −2% | +85% | +27% | +20% | +11% | −40% | +6% |
| Core profit YoY | — | — | — | +73% | +4% | −2% | +24% | +20% | +24% | +64% | +5% | +20% |
| EPS | ₹32.56 | ₹28.41 | ₹39.10 | ₹32.94 | ₹34.61 | ₹27.89 | ₹72.34 | ₹41.91 | ₹41.32 | ₹31.00 | ₹43.68 | ₹44.70 |
| Flags | · | · | 1 | ✓ | ✓ | ✓ | 2 | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Pfizer Ltd. reported revenue of ₹538 cr (−0.4% on the year) and net profit of ₹128 cr (−1.5% on the year) for October to December 2024.
Profit before other income, exceptional items and tax moved −2.3% on the year, against −1.5% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.